All In Biotech

Drug Trial Radar · NCT05128825

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Feb 17, 2022

Primary completion

Dec 1, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.

Conditions

  • High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Interventions

  • azenosertibDrug

    Azenosertib (ZN-c3) will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) defined by RECIST v1.1 [Part 2]Time frame: Up to approximately 12 months from the enrollment of the last subject

Locations

89 sites in 9 countries. Site status is shown where the registry gives one.

  • Site 0170-USA Mitchell Cancer Institute

    Mobile, Alabama · Recruiting

  • Site 0143 - HonorHealth

    Phoenix, Arizona · Recruiting

  • Site 0102 - University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • Site 0258 - UC San Diego Moores Cancer Center

    La Jolla, California · Active not recruiting

  • Site 0287 - Ridley Tree Cancer Center

    Santa Barbara, California · Active not recruiting

  • Site 0135 - Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Site 0158 - Hartford HealthCare

    Hartford, Connecticut · Recruiting

  • Site 0241 - Florida Cancer Specialist - North

    Altamonte Springs, Florida · Recruiting

  • Site 0173 - Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

  • Site 0308 - Advent Health

    Orlando, Florida · Recruiting

  • Site 0239 - Florida Cancer Specialists - East

    Wellington, Florida · Recruiting

  • Site 0108 - Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Site 0236 - Memorial Health

    Savannah, Georgia · Active not recruiting

  • Site 0324 - Illinois Cancer Specialists

    Niles, Illinois · Active not recruiting

  • Site 0284 - Community Cancer Center North

    Indianapolis, Indiana · Recruiting

  • Site 0217 - St Vincent Hospital and Health Care Centers

    Indianapolis, Indiana · Recruiting

  • Site 0251 - Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Site 0146 - Maryland Oncology Hematology, PA

    Rockville, Maryland · Active not recruiting

  • Site 0221 - Tufts Medical Center - PPDS

    Boston, Massachusetts · Recruiting

  • Site 0104 - Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Site 0307 - Lahey Hospital and Medical Center

    Burlington, Massachusetts · Recruiting

  • Site 0263 - Baystate Medical Center

    Springfield, Massachusetts · Recruiting

  • Site 0101 - Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Site 0228 - Corewell Health Medical Group West

    Grand Rapids, Michigan · Recruiting

  • Site 0288 - Minnesota Oncology Hematology - Maplewood

    Maplewood, Minnesota · Recruiting

  • Site 0226 - CoxHealth

    Springfield, Missouri · Active not recruiting

  • Site 0317 - Nebraska Methodist Hospital

    Omaha, Nebraska · Active not recruiting

  • Site 0213 - Center of Hope

    Reno, Nevada · Recruiting

  • Site 0231 - Northwell Health Cancer Institute

    Manhasset, New York · Active not recruiting

  • Site 0126 - Wilmot Cancer Center

    Rochester, New York · Recruiting

  • Site 0259 - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Site 0147 - Trihealth Cancer Institute - Harold and Eugen

    Cincinnati, Ohio · Recruiting

  • Site 0243 - Mark H Zangmeister Cancer Center

    Columbus, Ohio · Recruiting

  • Site 0214-Ohio State University Comprehensive Cancer Center

    Hilliard, Ohio · Recruiting

  • Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • Site 0232 - University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Site 0178 - Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Site 0277 - Alliance Cancer Specialist, PC

    Wynnewood, Pennsylvania · Active not recruiting

  • Site 0132 - Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • Site 0103 - University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.